Clinical Trial News and Research

RSS

Pulsar Vascular announces FDA approval of PulseRider IDE for intracranial bifurcation aneurysms

Pulsar Vascular, the innovator and developer of the PulseRider, a minimally invasive, aneurysm neck reconstruction device, announced today the United States Food and Drug Administration's approval of an Investigational Device Exemption (IDE) for the PulseRider.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

2014 DIA patient fellows illustrate the power of patient advocacy

The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Researchers uncover several gene networks with potentially important roles in autism

A large new analysis of DNA from thousands of patients has uncovered several underlying gene networks with potentially important roles in autism.

9 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Gene networks may offer attractive targets for developing new autism drugs

A large new analysis of DNA from thousands of patients has uncovered several underlying gene networks with potentially important roles in autism.

6 Jun 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

New drug shows promising results in patients with advanced pancreatic cancer

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.

6 Jun 2014

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Researchers at Shepherd Center are studying whether stimulating the brain before rehabilitation could yield greater gains in motor function for people recovering from stroke.

5 Jun 2014

Clinical Trial News and Research

Pulsar Vascular announces FDA approval of PulseRider IDE for intracranial bifurcation aneurysms

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

2014 DIA patient fellows illustrate the power of patient advocacy

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Researchers uncover several gene networks with potentially important roles in autism

Cardiac biomarkers aid microvascular risk prediction in diabetics

Gene networks may offer attractive targets for developing new autism drugs

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

New drug shows promising results in patients with advanced pancreatic cancer

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Study offers clues to best long-acting injectable antipsychotic use

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery